SK Biopharmaceuticals Co., Ltd.
SK Biopharmaceuticals is a KOSPI-listed (326030) company based in Seongnam. Its epilepsy drug cenobamate (Xcopri) is approved in the United States, and in 2026 it agreed to in-license the epilepsy candidate opakalim.
| Headquarters | Seongnam, South Korea |
|---|---|
| Listing | KOSPI:326030 |
| Lead asset / stage | cenobamate (Xcopri) Approved — United States |
| Latest event | SK Biopharmaceuticals announced an agreement to in-license epilepsy candidate opakalim. |